 Amryt Pharma PLC NASDAQ:AMYT, LON:AMYT said it hopes its gel designed to treat a rare skin disease will win fast-track approval from the US Food Drug Administration after finishing the rolling completion process. Its new drug application NDA for Oleogel-S10 could be reviewed in just six months under an expedited protocol that aims to bring through new products for rare ailments such as junctional and dystrophic epidermolysis bullosa EB. 